Logo.png
Duchenne Muscular Dystrophy (DMD) Clinical Trial Analysis Featuring 60+ Companies | DelveInsight
07 sept. 2022 13h00 HE | DelveInsight Business Research LLP
New York, USA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Duchenne Muscular Dystrophy (DMD) Clinical Trial Analysis Featuring 60+ Companies | DelveInsight Duchenne Muscular Dystrophy pipeline constitutes...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Second Quarter 2022 Financial Results
08 août 2022 16h01 HE | FibroGen, Inc.
Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021Continued significant...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Second Quarter 2022 Financial Results
25 juil. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report First Quarter 2022 Financial Results
25 avr. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
28 févr. 2022 16h01 HE | FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
04 janv. 2022 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C....
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at Upcoming Investor Conferences
02 nov. 2021 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Third Quarter 2021 Financial Results
26 oct. 2021 07h00 HE | FibroGen, Inc.
SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will...
OCHLogo.png
Option Care Health Selected as a Limited Distribution Provider of VILTEPSO™ (viltolarsen) Injection for Patients with Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy
02 sept. 2020 16h30 HE | Option Care Health, Inc.
BANNOCKBURN, Ill., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion...
2017 Capricor Final Logo v2@0.5x.png
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
19 déc. 2019 13h14 HE | Capricor Therapeutics, Inc.
LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics...